[Male breast cancer: clinical, pathologic and immunohistochemical study].
Forty-three cases of male breast cancer treated in the past 3 decades, comprising 1.92% of total cases of breast cancer in both sexes during the same period, were analyzed. Local skin involvement occurred in half of the patients. 67.7% of the patients presented axillary lymph node metastases and 82.9% were in stage II and III. Non-infiltrative and infiltrative specific cancers were diagnosed in 2 cases each, and infiltrative non-specific in 39 cases. Retrospective determination of estrogen receptor (ER) and carcinoembryonic antigen (CEA) in 33 specimens revealed positive ER in 57.6% and positive CEA in 72.7%. The more advanced the clinical stage, the higher is the positive rate of ER. Cases with positive CEA usually carried a more invasive process and a poorer prognosis. Immunohistochemical investigation in male breast cancer patients was valuable in the selection of post-operative adjuvant endocrine therapy or chemotherapy. Postoperative rise in serum CEA in patients with positive CEA may indicate recurrence.
R N
RN
Xu
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D002272:Carcinoembryonic Antigen / Q000032:analysis; D002277:Carcinoma / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D011960:Receptors, Estrogen / Q000032:analysis; D012189:Retrospective Studies
D002272:Carcinoembryonic Antigen; D011960:Receptors, Estrogen